Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC-Reference-Cited by-同舟云学术

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Published:2020-03 Issue:3 Volume:15 Page:324-343
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Tan Wan Ling,Chua Kevin L.M.,Lin Chia-Chi,Lee Victor H.F.,Tho Lye Mun,Chan Anthony W.,Ho Gwo Fuang,Reungwetwattana Thanyanan,Yang James C.,Kim Dong-Wan,Soo Ross A.,Ahn Yong Chan,Onishi Hiroshi,Ahn Myung-Ju,Mok Tony S.K.,Tan Daniel S.W.,Yang Fan

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference89 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

2. Preoperative staging of lung cancer with combined PET-CT;Fischer;N Engl J Med,2009

3. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer;Feinstein;N Engl J Med,1985

4. Therapeutic management options for stage III non–small cell lung cancer;Yoon;World J Clin Oncol,2017

5. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distant metastatic patterns in young and old non-small cell lung cancer patients: A dose‒response analysis based on SEER population;Heliyon;2024-09

2. Prognostic Value of Preoperative N Subcategories in Patients with Stage IIIA N2 Non–Small Cell Lung Cancer;Radiology: Cardiothoracic Imaging;2024-08-01

3. Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study;Radiotherapy and Oncology;2024-07

4. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study;Signal Transduction and Targeted Therapy;2024-06-14

5. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study;Cancer Immunology, Immunotherapy;2024-05-07